|
| 37985388 | Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. | Cancer | 2024 |
| 37856154 | Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. | Pediatr Blood Cancer | 2024 |
| 37985388 | Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. | Cancer | 2024 |
| 37856154 | Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. | Pediatr Blood Cancer | 2024 |
| 36351239 | Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. | Blood | 2023 |
| 36370087 | Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. | Pediatr Blood Cancer | 2023 |
| 35838057 | IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. | Pediatr Hematol Oncol | 2023 |
| 36351239 | Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. | Blood | 2023 |
| 35465865 | Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. | Infect Control Hosp Epidemiol | 2023 |
| 37776085 | Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN). | Pediatr Blood Cancer | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 36495256 | Data standards in pediatric oncology: Past, present, and future. | Pediatr Blood Cancer | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36815580 | Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database. | Pediatr Blood Cancer | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 37194639 | Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 37171449 | CD38 as a pan-hematologic target for chimeric antigen receptor TÂ cells. | Blood Adv | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 36669148 | Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. | J Clin Oncol | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 37776085 | Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN). | Pediatr Blood Cancer | 2023 |
| 35838057 | IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. | Pediatr Hematol Oncol | 2023 |
| 35465865 | Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. | Infect Control Hosp Epidemiol | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37171449 | CD38 as a pan-hematologic target for chimeric antigen receptor TÂ cells. | Blood Adv | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 37194639 | Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 36815580 | Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database. | Pediatr Blood Cancer | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36669148 | Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. | J Clin Oncol | 2023 |
| 36495256 | Data standards in pediatric oncology: Past, present, and future. | Pediatr Blood Cancer | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36370087 | Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. | Pediatr Blood Cancer | 2023 |
| 34570002 | Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report. | J Patient Saf | 2022 |
| 35705524 | Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. | Clin Cancer Res | 2022 |
| 35870472 | Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. | Lancet Haematol | 2022 |
| 35550034 | Factors that contribute to disparities in time to acute leukemia diagnosis in young people: an in depth qualitative interview study. | BMC Cancer | 2022 |
| 36198128 | Automated Ascertainment of Typhlitis From the Electronic Health Record. | JCO Clin Cancer Inform | 2022 |
| 36123353 | Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. | Nat Commun | 2022 |
| 34992254 | Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. | Bone Marrow Transplant | 2022 |
| 34990262 | Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. | J Clin Oncol | 2022 |
| 34570002 | Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report. | J Patient Saf | 2022 |
| 34855461 | CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. | J Clin Oncol | 2022 |